Is it acceptable to use TCHP instead of AC-T + trastuzumab as neoadjuvant chemotherapy for HER2+ inflammatory breast cancer?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Her2+ • University of Utah • NCI-CCC Breast Tumor Board Question

Patient case is triple positive inflammatory breast cancer

Answer from: Medical Oncologist at Academic Institution

Yes. With the Neosphere trial demonstrating an impressive PCR rate for the TCHP regimen, the TRAIN-2 trial showing no difference in outcomes with anthracycline containing vs non-anthracycline regimen and the BCIRG-006 trial long term follow showing that only 7 DFS events separating AC-TH and TCH, I ...

Comments

Medical Oncologist at McLeod Oncology and Hematology Associates
Wouldn’t you consider anthracycline because ...

Medical Oncologist at University of Nebraska Medical Center
There is no evidence to suggest a significant supe...

Medical Oncologist at Mercy Clinic Oncology - Fort Smith
What about hormone negative HER2 positive inflamma...

Medical Oncologist at University of Nebraska Medical Center
Unless there is discordance in pathology with a tr...

Answer from: Medical Oncologist at Academic Institution

In general, TCH is approximately equal to ACT. In BCIRG006, the AC-TH arm outperformed TCH by a very small amount from a breast cancer standpoint, approximately offset by slightly higher cardiac toxicity. Both are appropriate; some might use the anthracycline/taxane-based combination to buy as much ...

Comments

Medical Oncologist at Mercy Clinic Oncology - Fort Smith
Will you recommend AC-TH instead of TCH for hormon...

Medical Oncologist at Kettering Cancer Care
I agree that TCHP is equivalent to AC-TH with less...

Related Questions